Flavors and fragrances maker IFF's Q3 sales beat; low end of 2026 outlook raised
Overview
Flavors and fragrances maker's Q3 sales rose 4%, beating analyst expectations
Adjusted EPS for Q3 beat analyst expectations
Company completed $500 mln share repurchase and raised low end of full-year guidance
Outlook
IFF raises low end of 2026 sales outlook to $7.5 bln-$7.6 bln from $7.4 bln-$7.6 bln
Company lifts 2026 adjusted operating EBITDA guidance to $1.55 bln-$1.60 bln from $1.53 bln-$1.60 bln
IFF expects 2026 comparable currency neutral sales growth of 3%-4%, up from 2%-4% previously
Result Drivers
VOLUME GROWTH - Co said broad-based volume growth drove sales increases across all divisions, with Taste and Scent segments seeing mid-single digit gains and Health & Biosciences posting low-single digit growth
SEGMENT PERFORMANCE - Taste and Scent segments delivered strong top- and bottom-line results, while Health & Biosciences improved modestly, according to CEO Erik Fyrwald
COSTS AND REINVESTMENT - Co said higher costs and reinvestments in Health & Biosciences are expected to impact profitability, particularly in Q4
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | $1.94 bln | $1.91 bln (13 Analysts) |
Q3 Adjusted EPS | Beat | $0.83 | $0.80 (14 Analysts) |
Q3 Net Loss | $55 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the food processing peer group is "buy"
Wall Street's median 12-month price target for International Flavors & Fragrances Inc. is $100.00, about 5.7% above its November 2 closing price of $94.63
The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 17 three months ago
Reuters Recommended Reads
Nov 3 - Unilever targets $1.12 billion savings in home, personal care pivot
Nov 3 - Keurig Dr Pepper flags slower fourth-quarter coffee profits as shoppers trade down
Nov 2 - Clorox Q1 results beat estimates; expects FY adj EPS near low end of guidance range
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)